立方制药: 关于转让参股公司部分股权的公告

Transaction Overview - Hefei Lifan Pharmaceutical Co., Ltd. plans to transfer 2.2184% equity in Nanjing Mainowei Pharmaceutical Technology Co., Ltd. for a price of 22.183748 million RMB [1] - The company currently holds 6.4984% equity in Mainowei, which will decrease to 4.2800% after the transfer [1] - The transfer does not constitute a related party transaction or a major asset restructuring as per regulations [1] Counterparty Information - The buyer, Chengdu Yuanheyuandian Venture Capital Partnership, is a limited partnership established on November 6, 2023, with a registered capital of 1.961 billion RMB [2] - The main shareholders include several venture capital firms, with no significant conflicts of interest identified [2] Target Company Information - Nanjing Mainowei Pharmaceutical Technology Co., Ltd. was established on February 7, 2021, with a registered capital of 5.256734 million RMB [4] - The company reported total assets of 11.36144 million RMB and net assets of 8.73122 million RMB as of December 31, 2024 [4] - Mainowei's business includes the production of medical devices and pharmaceuticals, with recent financials showing a net loss of 3.12407 million RMB for the first quarter of 2025 [4] Agreement Details - The equity transfer agreement stipulates a payment structure where 50% of the transfer price is paid upfront and the remaining 50% within 15 working days after the first payment [5] - The agreement includes various conditions that must be met before the transfer is finalized, including due diligence and legal compliance [6][7] Impact on Company - The transaction is expected to generate a pre-tax profit of approximately 17.9876 million RMB, impacting the company's financials for 2025 [10] - The board believes the transaction is fair and will not adversely affect the company's operations or shareholder interests [10]